Fig. 3From: Uro-Vaxom® versus placebo for the prevention of recurrent symptomatic urinary tract infections in participants with chronic neurogenic bladder dysfunction: a randomised controlled feasibility studyInter-relationship between sponsor, funding, research governance, study management and clinical research sitesBack to article page